Literature DB >> 33450972

Feasibility of a Pilot Randomized Controlled Trial Examining a Multidimensional Intervention in Women with Gynecological Cancer at Risk of Lymphedema.

Shirin M Shallwani1,2,3, Anna Towers1,4, Anne Newman1, Shannon Salvador5, Angela Yung1,2, Lucy Gilbert4,6,7, Walter H Gotlieb4,5,6, Xing Zeng7, Doneal Thomas1.   

Abstract

There is limited knowledge on non-invasive lymphedema risk-reduction strategies for women with gynecological cancer. Understanding factors influencing the feasibility of randomized controlled trials (RCTs) can guide future research. Our objectives are to report on the design and feasibility of a pilot RCT examining a tailored multidimensional intervention in women treated for gynecological cancer at risk of lymphedema and to explore the preliminary effectiveness of the intervention on lymphedema incidence at 12 months. In this pilot single-blinded, parallel-group, multi-centre RCT, women with newly diagnosed gynecological cancer were randomized to receive post-operative compression stockings and individualized exercise education (intervention group: IG) or education on lymphedema risk-reduction alone (control group: CG). Rates of recruitment, retention and assessment completion were recorded. Intervention safety and feasibility were tracked by monitoring adverse events and adherence. Clinical outcomes were evaluated over 12 months: presence of lymphedema, circumferential and volume measures, body composition and quality of life. Fifty-one women were recruited and 36 received the assigned intervention. Rates of recruitment and 12-month retention were 47% and 78%, respectively. Two participants experienced post-operative cellulitis, prior to intervention delivery. At three and six months post-operatively, 67% and 63% of the IG used compression ≥42 h/week, while 56% engaged in ≥150 weekly minutes of moderate-vigorous exercise. The cumulative incidence of lymphedema at 12 months was 31% in the CG and 31.9% in the IG (p = 0.88). In affected participants, lymphedema developed after a median time of 3.2 months (range, 2.7-5.9) in the CG vs. 8.8 months (range, 2.9-11.8) in the IG. Conducting research trials exploring lymphedema risk-reduction strategies in gynecological cancer is feasible but challenging. A tailored intervention of compression and exercise is safe and feasible in this population and may delay the onset of lymphedema. Further research is warranted to establish the role of these strategies in reducing the risk of lymphedema for the gynecological cancer population.

Entities:  

Keywords:  cellulitis; compression; edema; exercise; feasibility; gynecological cancer; lymphedema; physical activity

Year:  2021        PMID: 33450972      PMCID: PMC7903266          DOI: 10.3390/curroncol28010048

Source DB:  PubMed          Journal:  Curr Oncol        ISSN: 1198-0052            Impact factor:   3.677


  63 in total

1.  [Stemmer's sign--possibilities and limits of clinical diagnosis of lymphedema].

Authors:  R Stemmer
Journal:  Wien Med Wochenschr       Date:  1999

Review 2.  Clinical trials needed to evaluate compression therapy in breast cancer related lymphedema (BCRL). Proposals from an expert group.

Authors:  H Partsch; N Stout; I Forner-Cordero; M Flour; C Moffatt; A Szuba; D Milic; G Szolnoky; H Brorson; M Abel; J Schuren; F Schingale; S Vignes; N Piller; W Döller
Journal:  Int Angiol       Date:  2010-10       Impact factor: 2.789

3.  Understanding the Hawthorne effect.

Authors:  Philip Sedgwick; Nan Greenwood
Journal:  BMJ       Date:  2015-09-04

4.  Incidence and risk factors for lower limb lymphedema after gynecologic cancer surgery with initiation of periodic complex decongestive physiotherapy.

Authors:  Imari Deura; Muneaki Shimada; Keiko Hirashita; Maki Sugimura; Seiya Sato; Shinya Sato; Tetsuro Oishi; Hiroaki Itamochi; Tasuku Harada; Junzo Kigawa
Journal:  Int J Clin Oncol       Date:  2014-07-04       Impact factor: 3.402

5.  Weight lifting in patients with lower-extremity lymphedema secondary to cancer: a pilot and feasibility study.

Authors:  Elana Katz; Nicole L Dugan; Joy C Cohn; Christina Chu; Rebecca G Smith; Kathryn H Schmitz
Journal:  Arch Phys Med Rehabil       Date:  2010-07       Impact factor: 3.966

6.  Lymphedema following gynecological cancer: Results from a prospective, longitudinal cohort study on prevalence, incidence and risk factors.

Authors:  Sandra C Hayes; Monika Janda; Leigh C Ward; Hildegard Reul-Hirche; Megan L Steele; Johnathan Carter; Michael Quinn; Bruce Cornish; Andreas Obermair
Journal:  Gynecol Oncol       Date:  2017-06-16       Impact factor: 5.482

7.  Incidence and risk factors of lower-extremity lymphedema after radical surgery with or without adjuvant radiotherapy in patients with FIGO stage I to stage IIA cervical cancer.

Authors:  Jin Hwi Kim; Ji Hyang Choi; Eun Young Ki; Sung Jong Lee; Joo Hee Yoon; Keun Ho Lee; Tae Chul Park; Jong Sup Park; Seog Nyeon Bae; Soo Young Hur
Journal:  Int J Gynecol Cancer       Date:  2012-05       Impact factor: 3.437

8.  Frequency and risk factors of lower limb lymphedema following lymphadenectomy in patients with gynecological malignancies.

Authors:  N Graf; K Rufibach; A M Schmidt; M Fehr; D Fink; A C Baege
Journal:  Eur J Gynaecol Oncol       Date:  2013       Impact factor: 0.196

9.  Aetiology and prevalence of lower limb lymphoedema following treatment for gynaecological cancer.

Authors:  Mary Ryan; M Colleen Stainton; Emma K Slaytor; Carmel Jaconelli; Sally Watts; Patricia Mackenzie
Journal:  Aust N Z J Obstet Gynaecol       Date:  2003-04       Impact factor: 2.100

10.  A randomized study to prevent lymphedema in women treated for breast cancer: CALGB 70305 (Alliance).

Authors:  Electra D Paskett; Jennifer Le-Rademacher; Jill M Oliveri; Heshan Liu; Drew K Seisler; Jeffrey A Sloan; Jane M Armer; Michelle J Naughton; Karen Hock; Michael Schwartz; Gary Unzeitig; Marianne Melnik; Lisa D Yee; Gini F Fleming; John R Taylor; Charles Loprinzi
Journal:  Cancer       Date:  2020-10-20       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.